Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Revance Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Revance Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Revance Therapeutics Acquires Intellectual Property Portfolio of Botulinum Toxin from Botulinum Toxin Research Associates 12
Venture Financing 13
Revance Therapeutics Raises US$10 Million In Venture Financing 13
Revance Therapeutics Raises US$56 Million In Extended Series E Financing 14
Licensing Agreements 16
Mylan Enters into Licensing Agreement with Revance Therapeutics 16
Equity Offering 17
Revance Therapeutics Plans to Raise upto USD125 Million in Public Offering of Shares 17
Revance Therapeutics Raises USD167.1 Million in Public Offering of Shares 18
Revance Therapeutics Raises USD10.1 Million in Public Offering of Shares 20
Revance Therapeutics Raises USD134.6 Public Offering of Shares 21
Revance Therapeutics Raises USD10.8 Million in Public Offering of Shares 23
Revance Therapeutics Raises USD140.3 Million in Public Offering of Shares 24
Revance Therapeutics Completes IPO For US$110.4 Million 26
Revance Therapeutics Inc – Key Competitors 28
Revance Therapeutics Inc – Key Employees 29
Revance Therapeutics Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Nov 01, 2018: Revance releases third quarter 2018 results 31
Aug 02, 2018: Revance releases second quarter 2018 results 33
May 08, 2018: Revance Releases First Quarter 2018 Results 34
Feb 28, 2018: Revance Announces Fourth Quarter and Full Year 2017 Financial Results 35
Nov 02, 2017: Revance Releases Third Quarter 2017 Results 36
Aug 03, 2017: Revance Releases Second Quarter 2017 Results 37
May 09, 2017: Revance Releases First Quarter 2017 Results 38
Feb 27, 2017: Revance Releases Fourth Quarter and Full Year 2016 Results 39
Corporate Communications 41
Oct 11, 2018: Revance Therapeutics appoints Tobin C. Schilke as chief financial officer 41
May 09, 2018: Revance Therapeutics Announces Two Recent Additions to Its Management Team 42
May 01, 2018: Revance Therapeutics Appoints Caryn McDowell As SVP, General Counsel & Corporate Secretary 43
Sep 06, 2017: Revance Appoints Mark Foley to its Board of Directors 44
Aug 01, 2017: Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics 45
Product News 46
01/12/2017: Revance Therapeutics Enters into $6.4M Settlement with City of Warren Police and Fire Retirement System 46
Clinical Trials 47
Jun 05, 2017: Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial 47
May 18, 2017: Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial 49
May 01, 2017: Revance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis 51
Mar 07, 2017: Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines 52
Mar 03, 2017: Revance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting 53
Jan 26, 2017: BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017 54
Jan 18, 2017: Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017 55
Jan 05, 2017: Revance Provides Clinical Milestones and Financial Outlook for 2017 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Revance Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Revance Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Revance Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Revance Therapeutics Acquires Intellectual Property Portfolio of Botulinum Toxin from Botulinum Toxin Research Associates 12
Revance Therapeutics Raises US$10 Million In Venture Financing 13
Revance Therapeutics Raises US$56 Million In Extended Series E Financing 14
Mylan Enters into Licensing Agreement with Revance Therapeutics 16
Revance Therapeutics Plans to Raise upto USD125 Million in Public Offering of Shares 17
Revance Therapeutics Raises USD167.1 Million in Public Offering of Shares 18
Revance Therapeutics Raises USD10.1 Million in Public Offering of Shares 20
Revance Therapeutics Raises USD134.6 Public Offering of Shares 21
Revance Therapeutics Raises USD10.8 Million in Public Offering of Shares 23
Revance Therapeutics Raises USD140.3 Million in Public Offering of Shares 24
Revance Therapeutics Completes IPO For US$110.4 Million 26
Revance Therapeutics Inc, Key Competitors 28
Revance Therapeutics Inc, Key Employees 29
Revance Therapeutics Inc, Subsidiaries 30
List of Figures
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Revance Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
【免責事項】
http://www.globalresearch.jp/disclaimer